Air Liquide has entered into exclusive negotiations with global investment organisation EQT for the potential sale of its subsidiary Schülke & Mayr GmbH.
Headquartered in Germany, Schülke & Mayr has been a leader in infection prevention and hygiene for more than 130 years.
The company develops, produces and distributes antiseptics for wound care, disinfectants, medical and cosmetic skin care products and preservatives.
Air Liquide first announced the potential sale in November 2019, illustrating its strategy to review its business portfolio regularly and to focus on its core gases and healthcare businesses, thereby enhancing Air Liquide’s performance.
Air Liquide said it intends to continue to develop its healthcare activities, while providing Schülke & Mayr with the best opportunity for its long-term development.
If completed, the acquisition by EQT VIII fund will further support Schülke & Mayr’s next phase of growth and its innovation development.
Read more: Air Liquide looks to sell subsidiary
Read more: Air Liquide: 10,000 ventilators in 50 days
This transaction is subject to the final and definitive agreement between the parties and will be carried out in the framework of the relevant social processes including ongoing dialogue with the employee representatives’ bodies.
Furthermore, the transaction will be subject to antitrust and foreign investment clearances.